Neighbor communities in drug combination networks characterize synergistic effect.

Combination therapies are urgently needed for optimal clinical benefit, but an efficient strategy for rational discovery of drug combinations, especially combinations of experimental drugs, is still lacking. Consequently, we proposed here a network-based computational method to identify novel synergistic drug combinations. A large-scale drug combination network (DCN), which provides an alternative way to study the underlying mechanisms of drug combinations, was constructed by integrating 345 drug combination relationships, 1293 drug-target interactions and 15134 target-protein interactions. It was illustrated that synergistic drugs seldom have identical or directly connected targets, while most targets in DCN can be reached from every other by 2 to 4 edges (interactions). Accordingly, the concept 'neighbor community' was introduced to characterize the relationships between synergistic drugs by specifying the interactions between drug targets and their neighbor proteins in the context of DCN. A subsequent study revealed that the integrated topological and functional properties of neighbor communities can be employed to successfully predict drug combinations. It was shown that this method can achieve 88% prediction accuracy and 0.95 AUC (Area Under ROC Curve), demonstrating its good performance in specificity and sensitivity. Moreover, ten predicted synergistic drug combinations unknown to the method were confirmed by recent literature, and three predicted new combinations of experimental drug BI-2536 were validated by in vitro assays. The results suggested that this method provides a means to explore promising drug combinations at an earlier stage of the drug development process.

[1]  Xin Chen,et al.  DCDB: Drug combination database , 2010, Bioinform..

[2]  Chuang Liu,et al.  Prediction of Drug-Target Interactions and Drug Repositioning via Network-Based Inference , 2012, PLoS Comput. Biol..

[3]  Anagha Joshi,et al.  Enrichment and aggregation of topological motifs are independent organizational principles of integrated interaction networks. , 2011, Molecular bioSystems.

[4]  U. Alon,et al.  Protein Dynamics in Drug Combinations: a Linear Superposition of Individual-Drug Responses , 2010, Cell.

[5]  Hui Zhang,et al.  An integrated scheme for feature selection and parameter setting in the support vector machine modeling and its application to the prediction of pharmacokinetic properties of drugs , 2009, Artif. Intell. Medicine.

[6]  Holger Fröhlich,et al.  GOSim – an R-package for computation of information theoretic GO similarities between terms and gene products , 2007, BMC Bioinformatics.

[7]  Joshua D. Knowles,et al.  Efficient discovery of anti-inflammatory small molecule combinations using evolutionary computing , 2011, Nature chemical biology.

[8]  Eric B Haura,et al.  Phase I/II study of the Src inhibitor dasatinib in combination with erlotinib in advanced non-small-cell lung cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  Xue-Gang Yang,et al.  In silico prediction and screening of γ‐secretase inhibitors by molecular descriptors and machine learning methods , 2009, J. Comput. Chem..

[10]  Lennart Martens,et al.  The Protein Identifier Cross-Referencing (PICR) service: reconciling protein identifiers across multiple source databases , 2007, BMC Bioinformatics.

[11]  Xing-Ming Zhao,et al.  Prediction of Drug Combinations by Integrating Molecular and Pharmacological Data , 2011, PLoS Comput. Biol..

[12]  Dexter T. Duncan,et al.  Relating protein adduction to gene expression changes: a systems approach. , 2011, Molecular bioSystems.

[13]  Christian Sillaber,et al.  Polo-like kinase 1 (Plk1) as a novel drug target in chronic myeloid leukemia: overriding imatinib resistance with the Plk1 inhibitor BI 2536. , 2010, Cancer research.

[14]  A. Barabasi,et al.  Interactome Networks and Human Disease , 2011, Cell.

[15]  B Xie,et al.  Synergistic therapeutic actions of herbal ingredients and their mechanisms from molecular interaction and network perspectives. , 2009, Drug discovery today.

[16]  Alan Ashworth,et al.  Translating cancer research into targeted therapeutics , 2010, Nature.

[17]  Marc Ferrer,et al.  Parsimonious discovery of synergistic drug combinations. , 2011, ACS chemical biology.

[18]  Gianni Panagiotou,et al.  Mapping the genome of Plasmodium falciparum on the drug-like chemical space reveals novel anti-malarial targets and potential drug leads. , 2012, Molecular bioSystems.

[19]  Bo Zhang,et al.  A formal model for analyzing drug combination effects and its application in TNF-α-induced NFκB pathway , 2010, BMC Systems Biology.

[20]  Xiaobo Zhou,et al.  An enhanced Petri-net model to predict synergistic effects of pairwise drug combinations from gene microarray data , 2011, Bioinform..

[21]  Elie Dolgin When it takes two to tango, FDA suggests a new regulatory dance , 2011, Nature Medicine.

[22]  Yan Zhou,et al.  Evaluation of GO-based functional similarity measures using S. cerevisiae protein interaction and expression profile data , 2008, BMC Bioinformatics.

[23]  David J. Harrison,et al.  Systems pathology—taking molecular pathology into a new dimension , 2009, Nature Reviews Clinical Oncology.

[24]  Xiaohua Ma,et al.  Mechanisms of drug combinations: interaction and network perspectives , 2009, Nature Reviews Drug Discovery.

[25]  David S. Wishart,et al.  DrugBank 3.0: a comprehensive resource for ‘Omics’ research on drugs , 2010, Nucleic Acids Res..

[26]  Ines Gockel,et al.  Analysis of anti‐proliferative and chemosensitizing effects of sunitinib on human esophagogastric cancer cells: Synergistic interaction with vandetanib via inhibition of multi‐receptor tyrosine kinase pathways , 2009, International journal of cancer.

[27]  Yu-Quan Wei,et al.  Systems Biology Modeling Reveals a Possible Mechanism of the Tumor Cell Death upon Oncogene Inactivation in EGFR Addicted Cancers , 2011, PloS one.

[28]  Kara Dolinski,et al.  The BioGRID Interaction Database: 2011 update , 2010, Nucleic Acids Res..

[29]  Sandhya Rani,et al.  Human Protein Reference Database—2009 update , 2008, Nucleic Acids Res..

[30]  Livia Perfetto,et al.  MINT, the molecular interaction database: 2009 update , 2009, Nucleic Acids Res..

[31]  L. Lai,et al.  Finding multiple target optimal intervention in disease-related molecular network , 2008, Molecular systems biology.

[32]  R. Bernards,et al.  Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR , 2012, Nature.

[33]  Hanbing Rao,et al.  Identification of small molecule aggregators from large compound libraries by support vector machines , 2009, J. Comput. Chem..

[34]  Trey Ideker,et al.  Integrating physical and genetic maps: from genomes to interaction networks , 2007, Nature Reviews Genetics.

[35]  Sumithra J. Mandrekar,et al.  Phase I Trial of Sorafenib in Combination with Gefitinib in Patients with Refractory or Recurrent Non–Small Cell Lung Cancer , 2007, Clinical Cancer Research.

[36]  John P. Overington,et al.  ChEMBL: a large-scale bioactivity database for drug discovery , 2011, Nucleic Acids Res..

[37]  P. Sorger,et al.  Systems biology and combination therapy in the quest for clinical efficacy , 2006, Nature chemical biology.

[38]  J. Woodcock,et al.  Development of novel combination therapies. , 2011, The New England journal of medicine.

[39]  Michelle S. Scott,et al.  Chemogenomic profiling predicts antifungal synergies , 2009, Molecular systems biology.

[40]  Yang Song,et al.  Therapeutic target database update 2012: a resource for facilitating target-oriented drug discovery , 2011, Nucleic Acids Res..

[41]  Michael Costanzo,et al.  Systematic exploration of synergistic drug pairs , 2011, Molecular systems biology.

[42]  Robert Clarke,et al.  Dynamic modelling of oestrogen signalling and cell fate in breast cancer cells , 2011, Nature Reviews Cancer.

[43]  Alona Muzikansky,et al.  Capecitabine plus erlotinib in gemcitabine-refractory advanced pancreatic cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[44]  D. Lauffenburger,et al.  Physicochemical modelling of cell signalling pathways , 2006, Nature Cell Biology.

[45]  T. Gilmer,et al.  Synergistic Effects of Foretinib with HER-Targeted Agents in MET and HER1- or HER2-Coactivated Tumor Cells , 2011, Molecular Cancer Therapeutics.

[46]  Susumu Goto,et al.  KEGG for integration and interpretation of large-scale molecular data sets , 2011, Nucleic Acids Res..

[47]  Chih-Jen Lin,et al.  Working Set Selection Using Second Order Information for Training Support Vector Machines , 2005, J. Mach. Learn. Res..

[48]  Yu-Quan Wei,et al.  Integrated computational model of cell cycle and checkpoint reveals different essential roles of Aurora-A and Plk1 in mitotic entry. , 2011, Molecular bioSystems.

[49]  C. Sander,et al.  Models from experiments: combinatorial drug perturbations of cancer cells , 2008, Molecular systems biology.

[50]  A. Barabasi,et al.  Network medicine : a network-based approach to human disease , 2010 .

[51]  Bo Zhang,et al.  Network target for screening synergistic drug combinations with application to traditional Chinese medicine , 2011, BMC Systems Biology.

[52]  Rafael C. Jimenez,et al.  The IntAct molecular interaction database in 2012 , 2011, Nucleic Acids Res..

[53]  Jian Jin,et al.  Dynamic Reprogramming of the Kinome in Response to Targeted MEK Inhibition in Triple-Negative Breast Cancer , 2012, Cell.

[54]  Yiling Lu,et al.  Identification of optimal drug combinations targeting cellular networks: integrating phospho-proteomics and computational network analysis. , 2010, Cancer research.